Xuanwu Hospital, Capital Medical University
Beijing, Beijing Municipality, 100053, China
Location status: Recruiting
NCT Number: NCT06708143
This single-center prospective study aims to investigate the treatment efficacy of temporal interference (TI) in drug-resistant epilepsy patients aged 6-60.
Interested in participating?
Request Info6 year–60 year
All sexes
Interventional
Not applicable
Beijing, Beijing Municipality, 100053, China
Location status: Recruiting
Temporal Interference (TI) technology is a novel non-invasive method for deep brain stimulation (DBS). By generating an overlapping electric field from safe currents, TI creates focused stimulation in targeted deep brain areas. This approach allows for the exploration of deep brain nuclei functions and has the potential to serve as a non-invasive alternative to traditional invasive DBS for clinical treatments.
This study aims to investigate the treatment efficacy of TI deep brain stimulation by including drug-resistant patients aged 6-60. During and after TI stimulation, clinical and electrophysiology data will be recorded. Clinical, imaging and electrophysiology data will be analyzed and processed to advance the treatment of drug-resistant epilepsy.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Researchers apply temporal interference (TI) stimulation to the deep brain nuclei of drug resistant epilepsy patients.
Other names: TI
Time frame: Up to 1 year after TI stimulation
Seizure frequency (SF28) is defined as seizure count per month (28-day) period. The SF28 is calculated as follows, where D=total number of days for which seizure information is collected for the specific 28-day interval:
SF28=(Total number of seizures in D days/D)*28. In addition, the baseline seizure frequency is defined as mean of 3- month SF28 in the baseline period. The seizure frequency in double-blind phase is defined as SF28 per month during the double-blind period. Percent change in seizure frequency=100*(double-blind SF28-baseline SF28)/baseline SF28.
Time frame: Up to 1 year after TI stimulation
The proportion of patients with a ≥ 50% reduction from Baseline in seizure frequency.
Time frame: Up to 1 year after TI stimulation
Percentage change from baseline in Quality of Life in Epilepsy-31 inventory (QOLIE-31) score. The minimum and maximum values, and whether higher scores mean a better or worse outcome.
Time frame: Up to 1 year after TI stimulation
Percentage change from baseline in Mini-Mental State Examination (MMSE) score. The MMSE score ranges from 0 to 30, with higher scores representing better cognitive function and lower scores indicating greater cognitive impairment.
Time frame: Up to 1 year after TI stimulation
Percentage change from baseline in Montreal Cognitive Assessment (MoCA) score. The MoCA score ranges from 0 to 30, with higher scores indicating better cognitive function and lower scores suggesting greater cognitive impairment.
Time frame: Up to 1 year after TI stimulation
Rate of adverse events which were judged to be study-related throughout the study.
Time frame: Up to 1 year after TI stimulation
The number presented is for Definite and Probable SUDEP. The rate is calculated per 1000 subject years of follow-up.
Contact information is provided by the study sponsor or research team.
Xuanwu Hospital, Beijing
Other
Noninvasive Temporal Interference Stimulation for the Treatment of Drug Resistant Epilepsy
Acronym: TIE
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07640191
Brain Diseases, Central Nervous System Diseases
South Brisbane, Queensland, Australia
View Trial DetailsNCT07399327
Brain Diseases, Central Nervous System Diseases
Marseille, France
View Trial DetailsNCT03868293
Brain Diseases, Central Nervous System Diseases
Boston, Massachusetts, United States
View Trial DetailsNCT06059157
Brain Diseases, Central Nervous System Diseases
Brussels, Belgium
View Trial Details